Directors' Dealings

5 February 2024

4basebio plc

(“4babsebio” or the "Company")
 

Directors’ Dealings

Cambridge, UK, 5 February 2024 - 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, thermostable nucleic acid delivery platform, announces that, further to its announcement of 2 February 2024, directors of the Company have sold shares in order to pay for options exercised as follows:

Name	Number of Shares Sold	Sale price per share (p)	Shareholding Following Sale	Shareholding as a Percentage of Issued Share Capital
Heikki Lanckriet	45,322	660p	1,418,994	11.09%
David Roth	38,292	660p	457,708	3.58%

The calculations above are based on an issued share capital of the Company of 12,796,208 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

4basebio PLC	[phone]
Heikki Lanckriet, CEO
Cairn Financial Advisers LLP (Nominated Adviser)	[phone]
Jo Turner / Sandy Jamieson
Cavendish Capital Markets Limited (Broker)	[phone]
Geoff Nash/Charlie Beeson

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Dr Heikki Lanckriet David Roth
2	Reason for notification
a.	Position/Status	CEO CFO
b.	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	4basebio plc
b.	LEI	213800E2DX9EAIUNCB30
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: GB00BMCLYF79
b.	Nature of the transaction	Sale of Ordinary Shares
			Price(s) per share (p)	Volume(s)
			660p 660p	45,322 38,292
d.	Aggregated information Volume Price	83,614 660 pence per share
e.	Date of the transaction	2/2/2024
f.	Place of the transaction	London Stock Exchange, AIM

---

---